Trillium Therapeutics (TRIL) vs. Soligenix (SNGX) Critical Comparison
Trillium Therapeutics (NASDAQ: TRIL) and Soligenix (OTC:SNGX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, profitability, risk, analyst recommendations and dividends.
Earnings and Valuation
This table compares Trillium Therapeutics and Soligenix’s revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||NetIncome||Earnings Per Share||Price/Earnings Ratio|
|Trillium Therapeutics||N/A||N/A||-$23.96 million||($3.79)||-2.61|
Insider & Institutional Ownership
48.0% of Trillium Therapeutics shares are held by institutional investors. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
This table compares Trillium Therapeutics and Soligenix’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of recent recommendations for Trillium Therapeutics and Soligenix, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Trillium Therapeutics currently has a consensus price target of $12.50, indicating a potential upside of 26.26%. Soligenix has a consensus price target of $8.00, indicating a potential upside of 263.64%. Given Soligenix’s higher possible upside, analysts clearly believe Soligenix is more favorable than Trillium Therapeutics.
Risk & Volatility
Trillium Therapeutics has a beta of 1.53, meaning that its share price is 53% more volatile than the S&P 500. Comparatively, Soligenix has a beta of 1.7, meaning that its share price is 70% more volatile than the S&P 500.
About Trillium Therapeutics
Trillium Therapeutics Inc., a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The companys lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced hematologic malignancies and solid tumors therapy. Its product candidates also include TTI-622, an IgG4 SIRPaFc protein for combination therapy; bromodomain inhibitor; and epidermal growth factor receptor antagonist, which are in preclinical development stage, as well as undisclosed immuno-oncology targets that are in the discovery Phase. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was founded in 2004 and is headquartered in Mississauga, Canada.
Soligenix, Inc. is a late-stage biopharmaceutical company. The Company is focused on developing and commercializing products to treat rare diseases. The Company operates through two segments: BioTherapeutics and Vaccines/BioDefense. Its BioTherapeutics segment is developing a photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL), formulations of oral beclomethasone 17,21-dipropionate (BDP) for the prevention/treatment of gastrointestinal (GI) disorders characterized by severe inflammation, and its innate defense regulator (IDR) technology, dusquetide (SGX942) for the treatment of oral mucositis in head and neck cancer. Its Vaccines/BioDefense business segment includes active development programs for RiVax, its ricin toxin vaccine candidate, OrbeShield, its GI acute radiation syndrome (GI ARS) therapeutic candidate, and SGX943, its melioidosis therapeutic candidate.
Receive News & Ratings for Trillium Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trillium Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.